Cleveland Clinic Lerner Research Institute and Rensselaer are collaborating to further research at the intersection of medicine and engineering. The institutions will jointly undertake research in several areas including nano-medicine, nano-bio materials, smart orthopaedic implants, biomolecular imaging, biocomputation and bioinformatics, bio-MEMS and the development of drug delivery devices.

Recalls of popular prescription drugs are raising public concern about the general safety of new pharmaceuticals. A collaborative group of researchers at Rensselaer, University of California-Berkeley, and Solidus Biosciences Inc. says that identifying which drug candidates are toxic early in the discovery process can help prevent harmful pharmaceuticals from being placed on the market in the first place — and they have developed a tool to do it.

Rensselaer, in collaboration with IBM and New York state, has announced a $100 million partnership to create the world’s most powerful university-based supercomputing center, and a top 10 supercomputing center of any kind in the world. The CCNI will focus on reducing the time and costs associated with designing and manufacturing nanoscale materials, devices, and systems.